Human Genome Epidemiology Literature Finder
Records 1 - 8 (of 8 Records) |
Query Trace: Thrombocytopenia and BRCA2[original query] |
---|
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England journal of medicine 2009 Jul 361 (2): 123-34. Fong Peter C, Boss David S, Yap Timothy A, Tutt Andrew, Wu Peijun, Mergui-Roelvink Marja, Mortimer Peter, Swaisland Helen, Lau Alan, O'Connor Mark J, Ashworth Alan, Carmichael James, Kaye Stan B, Schellens Jan H M, de Bono Johann |
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. The Lancet. Oncology 2013 Aug 14 (9): 882-92. Sandhu Shahneen K, Schelman William R, Wilding George, Moreno Victor, Baird Richard D, Miranda Susana, Hylands Lucy, Riisnaes Ruth, Forster Martin, Omlin Aurelius, Kreischer Nathan, Thway Khin, Gevensleben Heidrun, Sun Linda, Loughney John, Chatterjee Manash, Toniatti Carlo, Carpenter Christopher L, Iannone Robert, Kaye Stan B, de Bono Johann S, Wenham Robert |
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology 2015 Jun 137 (3): 386-91. Coleman Robert L, Sill Michael W, Bell-McGuinn Katherine, Aghajanian Carol, Gray Heidi J, Tewari Krishnansu S, Rubin Steven C, Rutherford Thomas J, Chan John K, Chen Alice, Swisher Elizabeth |
BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2017 Nov . Kotsopoulos Joanne, Willows Karla, Trat Sandra, Kim Raymond H, Volenik Alexandra, Sun Ping, Narod Steven A, Boyd Jeffrey, May Taym |
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer chemotherapy and pharmacology 2019 8 84 (4): 791-798. Mirza Mansoor Raza, Bergmann Troels K, Mau-Sørensen Morten, Christensen René dePont, Åvall-Lundqvist Elisabeth, Birrer Michael J, Jørgensen Morten, Roed Henrik, Malander Susanne, Nielsen Flemming, Lassen Ulrik, Brøsen Kim, Bjørge Line, Mäenpää Johan |
Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients? Gynecologic oncology 2019 May . Tomao Federica, Musacchio Lucia, Di Mauro Federica, Boccia Serena Maria, Di Donato Violante, Giancotti Antonella, Perniola Giorgia, Palaia Innocenza, Muzii Ludovico, Benedetti Panici Pierlui |
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology 2020 8 21 (10): 1269-1282. Diéras Véronique, Han Hyo S, Kaufman Bella, Wildiers Hans, Friedlander Michael, Ayoub Jean-Pierre, Puhalla Shannon L, Bondarenko Igor, Campone Mario, Jakobsen Erik H, Jalving Mathilde, Oprean Cristina, Palácová Marketa, Park Yeon Hee, Shparyk Yaroslav, Yañez Eduardo, Khandelwal Nikhil, Kundu Madan G, Dudley Matthew, Ratajczak Christine K, Maag David, Arun Banu |
Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib. Biomedicines 2022 11 10 (11): . Botrus Gehan, Roe Denise, Jameson Gayle S, Junior Pedro Luiz Serrano Uson, Korn Ronald Lee, Caldwell Lana, Bargenquast Taylor, Miller Max, Borazanci Erkut Has |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: